TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05848245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction
Description: Dental sections are used to absorb aerosol particles generated when using dental instrument such as ultrasonic and high air driven handpieces, this aerosol is mixture of blood, saliva, infectious agents, and dental materials.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction
Description: Dental sections are used to absorb aerosol particles generated when using dental instrument such as ultrasonic and high air driven handpieces, this aerosol is mixture of blood, saliva, infectious agents, and dental materials.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction
Description: Dental sections are used to absorb aerosol particles generated when using dental instrument such as ultrasonic and high air driven handpieces, this aerosol is mixture of blood, saliva, infectious agents, and dental materials.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction
Description: Dental sections are used to absorb aerosol particles generated when using dental instrument such as ultrasonic and high air driven handpieces, this aerosol is mixture of blood, saliva, infectious agents, and dental materials.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction
Description: Dental sections are used to absorb aerosol particles generated when using dental instrument such as ultrasonic and high air driven handpieces, this aerosol is mixture of blood, saliva, infectious agents, and dental materials.
Study: NCT06317454

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and saliva analysis
Description: Phenotyping and genotyping characterization using blood and saliva

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and saliva analysis
Description: Phenotyping and genotyping characterization using blood and saliva
Study: NCT05488808

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: Deep rTMS is delivered with the Brainsway H7-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head targeting the primary motor cortex of the leg.
Study: NCT05770063

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: amino acid tablet
Description: multiple essential amino acids supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: amino acid tablet
Description: multiple essential amino acids supplements
Study: NCT05775835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration and strengthening exercise
Description: Prior to commencing training, all subjects will undergo a pre-screening that includes a thorough history and physical examination to monitor compliance with the inclusion criteria. Evaluation parameters will be evaluated before and after 6 weeks of exercise. Training sessions will be held 3 days a week for 6 weeks, with a minimum of 48 hours between training sessions. All exercise groups include a warm-up period and a cool-down period (stretching exercises). Stretching exercises for the hamstring, gastrocnemius, soleus, and quadriceps muscles will be performed for 15-30 seconds and 3-5 repetitions. The total average application time (including warm-up and cool-down exercises), consisting of exercise and rest periods, was planned as 45-60 minutes for the WBV, SE, and WBV+SE groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise
Description: The application will be carried out with a whole body vibration device that gives 35 Hz constant vertical vibration. The exercises will be performed on the vibration platform in a standing position and with vibration. 5 static squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squat on the fingertip (120 degrees knee extension), right and left lunge positions, which will be accepted as 180 degrees full knee extension exercise protocol. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For static exercises, the duration will be 3 sets of 30-60 seconds in each practice position. There will be 30-60 second rest breaks between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercise
Description: The exercises will be performed on the vibration platform but without vibration. Patients will be asked to hold a body bar corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases.
Study: NCT04931602

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan
Description: investigations for secondary causes of osteoporosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan
Description: investigations for secondary causes of osteoporosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan
Description: investigations for secondary causes of osteoporosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan
Description: investigations for secondary causes of osteoporosis
Study: NCT04727541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Neoadjuvant therapy with bintrafusp alfa
Study: NCT04698928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation
Description: Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
Study: NCT05878028

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: L-TIL, Tislelizumab, Docetaxel
Description: PD1 positive lymphocytes were collect, isolated, and expanded from peripheral blood, then infused back into the patient's body. Besides this, Tislelizumab and Docetaxel were used as combination therapy.
Study: NCT05300048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serabelisib
Description: serabelisib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serabelisib
Description: serabelisib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serabelisib
Description: serabelisib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serabelisib
Description: serabelisib administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serabelisib
Description: serabelisib administered orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Suppressing Diet
Description: 3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Suppressing Diet
Description: 3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Suppressing Diet
Description: 3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Suppressing Diet
Description: 3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Suppressing Diet
Description: 3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: nab-paclitaxel administered intravenously weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: nab-paclitaxel administered intravenously weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: nab-paclitaxel administered intravenously weekly
Study: NCT05017545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Administered: Intravenously (IV). Carfilzomib is administered intravenously, on two consecutive days, each week for three weeks per cycle. In this study, subjects will receive 2 cycles of carfilzomib. Dosing for each cycle is based on the recommended dosing for carfilzomib monotherapy in the package insert.~Carfilzomib is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma. In this study, carfilzomib will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Administered: Intravenously (IV). Carfilzomib is administered intravenously, on two consecutive days, each week for three weeks per cycle. In this study, subjects will receive 2 cycles of carfilzomib. Dosing for each cycle is based on the recommended dosing for carfilzomib monotherapy in the package insert.~Carfilzomib is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma. In this study, carfilzomib will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Administered: Intravenously (IV). Belatacept is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in highly sensitized subjects who are awaiting a kidney transplant.
Study: NCT05938049

Intervention type: DEVICE
Intervention: IVC ultrasound & Carotid doppler
Description: bed side ultrasonographic assessement of inferior vena cava maximum and minimum diameters 2 to 5 cm caudal to its junction with the right atrium over a single respiratory cycle , inferior vena cava collapsibility index (IVC-CI) will calculated as (IVC max - IVC min)/IVC max).~carotid doppler assessment (2-3 cm proximal to the carotid bulb in the longitudinal plane) of corrected carotid flow time(systole time/√cycle time) ,carotid artery peak velocity variation calculated as (\[PV max- PV min\]/PV mean) × 100, where PV mean = (PV max + PV min)/2. during three consecutive respiratory cycles. as part of their routine care and assessment
Study: NCT05744440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allogenic NK cells
Description: The relapsed/refractory AML after allo-HSCT patients will receive allogenic NK cells infusion up to 2 dose levels (1x10\^7/kg, 5x10\^7/kg) after chemotherapy with azacitidine
Study: NCT05811429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: 16 sessions for 8 weeks ,per week 2 sessions will be given.
Study: NCT05017545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Administered: Intravenously (IV). Belatacept is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in highly sensitized subjects who are awaiting a kidney transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 16 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 16 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.
Study: NCT05078489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action-observation therapy
Description: Action observation therapy involves the observation and perception of human movement performed by others. The observation of actions performed by others activates in the perceiver the same neural structures responsible for the actual execution of those same actions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will watch a natural landscape without any human.
Study: NCT04982094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid and Relationship Building Training
Description: Relationship Building Training (RBT) is a 2 hour training session conducted live over zoom, that aims to equip business advisors the communications skills they need to enhance trustworthiness and quality of the relationship with their clients.~Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~Two Booster sessions are delivered 1- and 3-months after the last MHFA session that aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Health First Aid
Description: Mental Health First Aid (MHFA) is a certified training program. It requires 5-7 hours of online course work followed by 2 x 2.5 hour live zoom sessions in addition to online reading, that aims to enhance mental health literacy and teach the skills needed to identify the signs of mental health conditions and to have a conversation with a person who may need professional help.~MHFA online training is conducted two-weeks before the two MHFA sessions (with a 1 day break in between each MHFA). Two Booster sessions are delivered 1- and 3-months after the last MHFA session. The Booster sessions aims to give participants the opportunity to consolidate their learning and share experiences applying the knowledge/skills gained.~Participants will also invite 2-3 of their small-business entrepreneur (SME) clients to join the study and complete 3 surveys to provide feedback on the success of the program.
Study: NCT06458764

Intervention type: OTHER
Intervention: Questionnaire
Description: none, it's a incidence-prevalence study

Intervention type: OTHER
Intervention: Questionnaire
Description: none, it's a incidence-prevalence study
Study: NCT06292897

Intervention type: OTHER
Intervention: observational study
Description: observational study
Study: NCT05873712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo BM biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lisocabtagene Maraleucel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo lymph node biopsy
Study: NCT06366581

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptomic analysis
Description: high-throughput sequencing technology

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptomic analysis
Description: high-throughput sequencing technology
Study: NCT05321316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: All study participants will undergo one 18F-FDG PET/CT scan.
Study: NCT05041127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06561750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rooibos tea
Description: Participants will be subjected to 12 g of rooibos tea per 1200 ml of freshly boiled water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will be subjected to 12 g per 1200 ml of freshly boiled water which is equivalent to 6 cups of tea
Study: NCT06562166

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: online adaptive radiotherapy
Description: Patients in ART group received daily online adaptive radiotherapy with a prescription dose of 50.4Gy/28f.
Study: NCT05975697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group to be applied FES
Description: In the first 24 hours after the thrombectomy procedure, the relatives of the patients in the experimental and control groups who meet the inclusion criteria will be informed by the researcher and their consent will be obtained.~FES treatment to the deltoid, triceps, extensor carpi radialis muscles for a total of 10 sessions, 30 minutes twice a day (in the morning and in the evening), for 5 days after the first 24th hour after the thrombectomy procedure in the experimental group patients (Program duration is 15 minutes and resting time is 15 minutes). minutes) will be applied.Patient information form (Appendix 1), Fugl-meyer upper extremity motor assessment scale (Appendix-2) and Quick DASH (Arm, Shoulder and Hand Injury Questionnaire Short Form) (Appendix-3) were given to both groups within the first 24 hours after the thrombectomy procedure. ) will be applied. All patients will be re-evaluated before and on the 5th day after treatment.
Study: NCT04913376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hilotherapy
Description: Constant cooling device for hands and feet.
Study: NCT05873712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study: NCT04791943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 10 MG
Description: 3 melatonin 10mg capsules will be given to the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose pill
Description: 3 lactose pills will be provided to the control arm
Study: NCT05631678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin; ASK120067
Description: Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASK120067;itraconazole
Description: Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
Study: NCT05461573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone
Description: LPRI-CF113 consists of 24 active white tablets containing drospirenone (DRSP) 4 mg followed by 4 active pink tablets containing DRSP 2.8 mg, taken orally once daily for 28 consecutive days, in consecutive cycles for 12 months (13 medication cycles) without a break in daily tablet intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone
Description: LPRI-CF113 consists of 24 active white tablets containing drospirenone (DRSP) 4 mg followed by 4 active pink tablets containing DRSP 2.8 mg, taken orally once daily for 28 consecutive days, in consecutive cycles for 12 months (13 medication cycles) without a break in daily tablet intake.
Study: NCT05179174

Intervention type: GENETIC
Intervention: blood sample examination
Description: droplet digital PCR in blood sample for research of mutations of GNA11 and GNAQ genes and the following microRNAs: miR - 506-514 cluster, hsamiR - 592 and hsa - miR - 199a - 5p.

Intervention type: GENETIC
Intervention: blood sample examination
Description: droplet digital PCR in blood sample for research of mutations of GNA11 and GNAQ genes and the following microRNAs: miR - 506-514 cluster, hsamiR - 592 and hsa - miR - 199a - 5p.
Study: NCT06358053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRTE7A2-01 TCR-T cell therapy
Description: Drug 1: Fludarabine + Cyclophosphamide Drug 2: Interleukin-2 Drug 3: CRTE7A2-01 TCR-T Cell
Study: NCT05197634

Intervention type: OTHER
Intervention: Not Applicable (observation)
Description: Questionnaire

Intervention type: OTHER
Intervention: Not Applicable (observation)
Description: Questionnaire
Study: NCT05811429

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates exercises
Description: 16 sessions for 8 weeks ,per week 2 sessions will be given.
Study: NCT05792397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TwiFlow-Thrombectomy Catheter System
Description: Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'
Study: NCT05270733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Subjects will receive ustekinumab for 8 weeks followed by guselkumab or risankizumab for 8 weeks.
Study: NCT06456580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection